Targeted treatment in COPD: a multi-system approach for a multi-system disease

David Anderson, William Macnee, David Anderson, William Macnee

Abstract

Chronic obstructive pulmonary disease is a varied condition when examined from a number of different perspectives including factors which influence disease development, pathological process and clinical features. There may be a complex interaction between the degree by which each of these processes influences the development of COPD and the subsequent clinical phenotype with which the patient presents. The varied host response and subsequent clinical phenotype has generated much interest in recent years. It is possible that failure of treatment to impact on mortality and reverse the disease process is because of the heterogeneous nature of the condition. Identification and targeted treatment of clinical and pathological phenotypes within the broad spectrum of COPD may therefore improve outcome. This article will review previous work which has attempted to phenotype COPD and identify if specific treatment for these phenotypes has been shown to be of benefit. It will examine the work on pathological processes and clinical manifestations, both pulmonary and systemic, and will focus on pharmacological therapies.

Keywords: COPD; clinical phenotypes; pathological phenotypes.

References

    1. Rabe K, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of chronci obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:532–55.
    1. Silverman EKSF. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am. 1996;80:501–522.
    1. Løkke APL, Scharling H, Fabricius P, Vestbo J. Developing copd: A 25 year follow up study of the general population. Thorax. 2006;61:935–939.
    1. Tarjan E, Magyar P, Vaczi Z, Lantos A, Vaszar L. Longitudinal lung function study in heterozygous pimz phenotype subjects. Eur Respir J. 1994;7(12):2199–2204.
    1. Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: Findings from the british women’s heart and health study and a meta-analysis. Thorax. 2005;60(10):851–858.
    1. Anastassios C, Koumbourlis EKM, Mutich RL, Mallory GB, Jr, Walczak SA, Fertal K. Longitudinal follow-up of lung function from childhood to adolescence in prematurely born patients with neonatal chronic lung disease. Pediatr Pulmonol. 1996;21(1):28–34.
    1. Li Y-F, Gilliland FD, Berhane K, et al. Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma. Am J Respir Crit Care Med. 2000;162(6):2097–2104.
    1. Strachan D, Cox B, Erzinclioglu S, Walters D, Whichelow M. Ventilatory function and winter fresh fruit consumption in a random sample of british adults. Thorax. 1991;46(9):624–629.
    1. Prescott E, Bjerg A, Andersen P, Lange P, Vestbo J. Gender difference in smoking effects on lung function and risk of hospitalization for copd: Results from a danish longitudinal population study. Eur Respir J. 1997;10(4):822–827.
    1. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for copd: Results from the copenhagen city heart study. Eur Respir J. 1999;13(5):1109–1114.
    1. American Thoracic Society ERS. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: A statement of the american thoracic society and european respiratory society. Am J Respir Crit Care Med. 1999;159:S1–40.
    1. Biskobing DM. Copd and osteoporosis. Chest. 2002;121(2):609–620. doi: 10.1378/chest.121.2.609.
    1. Sin DD. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519.
    1. Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: Results from the copenhagen city heart study. Eur Respir J. 2002;20(3):539–544.
    1. Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2005;12(2):113–117.
    1. MacNee W. Oxidants/antioxidants and copd. Chest. 2000;117:303S–317S.
    1. Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;12(2):380–386.
    1. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164(3):469–473.
    1. Jeffery P. Structural and inflammatory changes in copd: A comparison with asthma. Thorax. 1998;53:129–136.
    1. Saetta M, Stefano A, Maestrelli P, et al. Activated t-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147:301–306.
    1. Janoff A. Biochemical links between cigarette smoking and pulmonary emphysema. J Appl Physiol. 1983;55(2):285–293.
    1. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur Respir J. 2005;25(3):552–563.
    1. Agustí A, MacNee W, Donaldson K, Cosio M. Hypothesis: Does copd have an autoimmune component. Thorax. 2003;58:832–834.
    1. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):778–784.
    1. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115(4):957–965.
    1. Belman M, Botnick W, Shin J. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(3):967–975.
    1. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224.
    1. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125(1):249–259.
    1. Stockley RAWP, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: Results of a meta-analysis. Respir Res. 2006;7:147.
    1. Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006;61(10):854–862.
    1. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.
    1. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. The European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340(25):1948–1953.
    1. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The isolde trial. BMJ. 2000;320(7245):1297–1303.
    1. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.
    1. Calverley PRP, Vestbo J, Jones P, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet. 2003;361(9356):449–456.
    1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with copd: A summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
    1. Calverley PMA, Anderson JA, Celli B, et al. the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
    1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919.
    1. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391–398.
    1. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1:681–685.
    1. Wedzicha J, Bestall J, Garrod R, Garnham R, Paul E, Jones P. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the mrc dyspnoea scale. Eur Respir J. 1998;12(2):363–369.
    1. Macnee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol. 2001;429:195–207.
    1. Heffner JA, Repine JE. State of the art: Pulmonary strategies of antioxidant defense. Am Rev Respir Dis. 1989;140:531–554.
    1. Halliwell B. Antioxidants in human health and disease. Ann Rev Nutr. 1996;16:33–50.
    1. Rahman I, van Schadewijk AAM, Crowther AJL, et al. 4-hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(4):490–495.
    1. Gilmour PS, Rahman I, Donaldson K, MacNee W. Histone acetylation regulates epithelial il-8 release mediated by oxidative stress from environmental particles. Am J Physiol Lung Cell Mol Physiol. 2003;284(3):L533–540.
    1. Lentsch A, Czermak B, Bless N, Van Rooijen N, Ward P. Essential role of alveolar macrophages in intrapulmonary activation of nf-kappa b. Am J Respir Cell Mol Biol. 1999;20(4):692–698.
    1. Warren JSJK, Ward PA. Consequences of oxidant injury. In: Crystal RG, West JB, Weibel ER, Barnes PJ, editors. The Lung: Scientific Foundations. New York, NY: Raven Press Ltd; 1997. pp. 2279–2288.
    1. Comhair SAA, Erzurum SC. Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol. 2002;283(2):L246–255.
    1. Lappas M, Permezel M, Rice GE. N-acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappab deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab. 2003;88(4):1723–1729.
    1. Rogers DF. Inhibition by oral n-acetylcysteine of cigarette smoke-induced “bronchitis” in the rat. Exp Lung Res. 1986;10:267–283.
    1. Rubio ML, Martin-Mosquero MC, Ortega M, Peces-Barba G, Gonzalez-Mangado N. Oral n-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest. 2004;125(4):1500–1506.
    1. Bridgeman M, Marsden M, MacNee W, Flenley D, Ryle A. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with n-acetylcysteine. Thorax. 1991;46(1):39–42.
    1. Bridgeman M, Marsden M, Selby C, Morrison D, MacNee W. Effect of n-acetyl cysteine on the concentrations of thiols in plasma, bronchialveolar lavage fluid, and lung tissue. Thorax. 1994;49(7):670–675.
    1. Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R. Effects of oral n-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J. 1988;1(7):645–650.
    1. Kasielski M. Long-term administration of n-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001;95:448–56.
    1. Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):795–798.
    1. Black P, Morgan-Day A, McMillan T, Poole P, Young R. Randomised, controlled trial of n-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2004;4(1):13.
    1. Poole P, Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review. BM J. 2001;322(7297):1271.
    1. Stey C, Steurer J, Bachmann S, Medici T, Tramer M. The effect of oral n-acetylcysteine in chronic bronchitis: A quantitative systematic review. Eur Respir J. 2000;16(2):253–262.
    1. Decramer M, Rutten-van Molken M, Dekhuijzen PR, et al. Effects of n-acetylcysteine on outcomes in chronic obstructive pulmonary disease (bronchitis randomized on nac cost-utility study, broncus): A randomised placebo-controlled trial. Lancet. 2005;365(9470):1552–1560.
    1. Rahman I. Oxidative stress, chromatin remodelling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol. 2003;36:95–109.
    1. Bosken CH, Hards J, Gatter K, Hogg JC. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis. 1992;145:911–917.
    1. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158(4):1277–1285.
    1. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of in smokers are FEV1 associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267–271.
    1. Finkelstein R, Fraser R, Ghezzo H, Cosio M. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995;152(5):1666–1672.
    1. MacNee W. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease. Trends Mol Med. 2001;7:55–62.
    1. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in chronic obstructive pulmonary disease is mediated by interleukin-8 (abstract) Am J Respir Crit Care Med. 1996;153:A821.
    1. Selby C, Drost E, Lannan S, Wraith PK, MacNee W. Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;143:1359–1364.
    1. American thoracic society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;1995;152:S77–121.
    1. Russell REK, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: Roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol. 2002;283(4):L867–873.
    1. Di Stefano A, Caramori G, Oates T, et al. Increased expression of nuclear factor-{kappa}b in bronchial biopsies from smokers and patients with COPD. Eur Respir J. 2002;20(3):556–563.
    1. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003;58(4):348–351.
    1. Riise G, Ahlstedt S, Larsson S, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax. 1995;50(4):360–365.
    1. Rusznak C, Mills PR, Devalia JL, Sapsford RJ, Davies RJ, Lozewicz S. Effect of cigarette smoke on the permeability and il-1beta and sicam-1 release from cultured human bronchial epithelial cells of never-smokers, smokers, and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2000;23(4):530–536.
    1. Park S-W, Lee YM, Jang AS, et al. Development of chronic airway obstruction in patients with eosinophilic bronchitis: A prospective follow-up study. Chest. 2004;125(6):1998–2004.
    1. Hargreave FE, Leigh R. Induced sputum, eosinophilic bronchitis, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(5):S53–57.
    1. Rutgers SR, Postma DS, ten Hacken NHT, et al. Ongoing airway inflammation in patients with copd who do not currently smoke. Thorax. 2000;55(1):12–18.
    1. Lams BEA, Sousa AR, Rees PJ, Lee TH. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(5):1518–1523.
    1. Brightling CE, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet. 2000;356(9240):1480–1485.
    1. Chavannes NH, Schermer TR, Jacobs JA, et al. Patterns of inflammation and the use of reversibility testing in smokers with airway complaints. BMC Pulm Med. 2006;6:11.
    1. Jatakanon A, Lalloo UG, Lim S, Chung KF, Barnes PJ. Increased neutrophils and cytokines, tnf-alpha and il-8, in induced sputum of non-asthmatic patients with chronic dry cough. Thorax. 1999;54(3):234–237.
    1. Radomski MW, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res. 1993;27:1380–1382.
    1. Leeper-Woodford SKDK. Acute hypoxia increases alveolar macrophage tumor necrosis factor activity and alters nf-kb expression. Am J Physiol. 1999;276:L909–916.
    1. Regnier CH SH, Gao X, et al. Identification and characterisation of an ib kinase. Cell. 1997;90:373–383.
    1. Beg AA, Finco TS, Nantermet PV, Baldwin AS., Jr Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of i kappa b alpha: A mechanism for nf-kappa b activation. Mol Cell Biol. 1993;13(6):3301–3310.
    1. Keatings VM, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530–534.
    1. Di Francia M, Barbier D, Mege J, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;150(5):1453–1455.
    1. Rennard SI, Fogarty C, Kelsen S, et al. on behalf of the COPD Investigator. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926–934.
    1. Pitsiou G, Hatzizisi O, Argyropoulou P, Mavrofridis E, Patakas D. Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir Med. 2002;96(8):594–598.
    1. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(8):1414–1418.
    1. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellularmechanisms. Eur Respir J. 2003;22(4):672–688.
    1. Kumar RK, Herbert C, Thomas PS, et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther. 2003;307(1):349–355.
    1. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (ariflo) on tnf-{alpha}, il-8, and gm-csf release by airway cells of patients with COPD. Thorax. 2003;58(7):573–579.
    1. Belleguic C, Corbel M, Germain N, Boichot E, Delaval P, Lagente V. Reduction of matrix metalloproteinase-9 activity by the selective phosphodiesterase 4 inhibitor, r73–401 in sensitized mice. Eur J Pharmacol. 2000;404(3):369–373.
    1. Martina SD, Ismail MS, Vesta KS. Cilomilast: Orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2006;40(10):1822–1828.
    1. Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet. 366(9485):563–571.
    1. Calverley PMA, Sanchez-Toril F, McIvor A, Teichmann P, Breden-broeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–161.
    1. Mahler D, Huang S, Tabrizi M, Bell G. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD. Chest. 2004;126:926–934.
    1. Fitzgerald MF, Fox JC. Emerging trends in the therapy of copd: Novel anti-inflammatory agents in clinical development. Drug Discov Today. 2007;12:11–12. 479–486.
    1. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP. Therapeutic potential of treating chronic obstructive pulmonary disease (copd) by neutralising granulocyte macrophage-colony stimulating factor (gm-csf) Pharmacol Ther. 2006;112(1):106–115.
    1. Nakamura H YK, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992;89:1478–1484.
    1. Senior RM, Kuhn C, Ohlsson K, Starcher BC, Pierce JA. The induction of pulmonary emphysema with human leukocyte elastase. The induction of pulmonary emphysema with human leukocyte elastase. 1977;116:469–475.
    1. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med. 2002;166(7):954–960.
    1. Chapman HA, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63–68.
    1. Laurell CB, Ericksson S. The electrophoretic alpha-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scand J Clin Invest. 1963;15:132–140.
    1. Sveger T. Agr1-antitrypsin deficiency in early childhood. Pediatrics. 1978;62(1):22–25.
    1. American thoracic society/european respiratory society statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.
    1. Lomas DA, Finch JT, et al. The mechanism of z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357:605–607.
    1. Wallaert BB, Gressier CH, Marquette P, et al. Inactivation of 1-proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema. Am Rev Respir Dis. 1993;147:1537–1543.
    1. Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest. 1987;80:1289–1295.
    1. Vogelmeier C, Fells GA, et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 87:482–488.
    1. Wewers MD, Sellers S, Swayze SC, McPhaul KM, Wittes JT, Crystal RG. Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316:1055–1062.
    1. Gadek JE, Holland PV, Crystal RG. Replacement therapy of alpha-1-antitrypsin deficiency: Reversal of protease–anti-protease balance within alveolar structures of pi z subjects. J Clin Invest. 1981;69:1158–1165.
    1. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in {alpha}1-anti-trypsin deficiency. Am J Respir Crit Care Med. 2002;165(11):1494–1498.
    1. Sandhaus RA. Alpha1-antitrypsin deficiency 6: New and emerging treatments for {alpha}1-antitrypsin deficiency. Thorax. 2004;59(10):904–909.
    1. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with {alpha}1-antitrypsin: Patterns of use and adverse events. Chest. 2003;123(5):1425–1434.
    1. Massaro GDC. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997;3:675–677.
    1. Fujita M, Ye Q, Ouchi H, et al. Retinoic acid fails to reverse emphysema in adult mouse models. Thorax. 2004;59(3):224–230.
    1. Mao JT, Goldin JG, Dermand J, et al. A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med. 2002;165(5):718–723.
    1. Roth MD, Connett JE, D’Armiento JM, et al. for the FORTE Study Investigators. Feasibility of retinoids for the treatment of emphysema study. Chest. 2006;130(5):1334–1345.
    1. Cantor JO, Shteyngart B, Cerreta JM, Turino GM. The effect of lysozyme on elastase-mediated injury. Exp Biol Med. 2002;227(2):108–113.
    1. Cantor JO, Armand G, Turino GM. Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc Soc Exp Biol Med. 1998;217:471–475.
    1. Cantor JO, Turino GM. Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? Chest. 2004;125(1):288–292.
    1. Bip Patel BM, Coxson HO, Muller NL, et al. Airway and parenchymal disease in chronic obstructive pulmonary disease are distinct phenotypes. Proc Am Thoracic Soc. 2006;3:533.
    1. Hironi Makita YN, Nagai Katsura, Ito Yoko, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62:932–937.
    1. Fujimoto K, Kubo K, Honda T. Clinical analysis of chronic obstructive pulmonary disease phenotypes classified using high-resolution computed tomography. Respirology. 2006;11:731–740.
    1. Boschetto P, Miniati M, Miotto D, et al. Predominant emphysema phenotype in chronic obstructive pulmonary disease patients. Eur Respir J. 2003;21(3):450–454.
    1. Cosio MG. Pathology of emphyesema in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 2000;55(2):124–129.
    1. Saetta M, Izquierdo JL, Ghezzo H, Cosio MG. Extent of centrilobular and panacinar emphysema in smokers’ lungs: Pathological and mechanical implications. Eur Respir J. 1994;7(4):664–671.
    1. Screaton NJ. Emphysema and smoking related diseases. Imaging. 2004;16:50–60.
    1. Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg. 1996;112(5):1319–1330.
    1. Calverley PMA. Closing the nett on lung volume reduction surgery. Thorax. 2003;58(8):651–653.
    1. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2007:200708–1194OC.
    1. De W. Quality of life after lung volume reduction surgery. Thorac Surg Clin. 2004;14(3):375–383.
    1. De W. Results of lung volume reduction surgery for emphysema. Chest Surg Clin N Am. 2003;13(4):709–726.
    1. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thoracic Soc. 2005;2:20–22.
    1. Kessler R, Faller M, Weitzenblum E, et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219–224.
    1. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36(10):752–758.
    1. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in copd patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107(5):1193–1198.
    1. Naeije R. Pulmonary hypertension associated with copd. Crit Care. 2001;5:586–589.
    1. Timms RM, Williams GW the Nocturnal Oxygen Therapy Trial Group. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985;(102):29–36.
    1. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: Current theories of pathogenesis and their implications for treatment. Thorax. 2005;60(7):605–609.
    1. Barbera J, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149(2):423–429.
    1. Rubin LJ, Badesch DB, Barst RJ, et al. the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.
    1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436.
    1. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20–22.
    1. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and decline in patients with chronic FEV1 obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(8):1090–1095.
    1. Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SJ, Wilkinson TMA, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of copd exacerbations. Eur Respir J. 2003;22(6):931–936.
    1. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J. 2004;23(5):685–691.
    1. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991–998.
    1. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of copd exacerbations. Thorax. 2002;57(9):759–764.
    1. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax. 2003;58(8):680–685.
    1. Southern KW, Barker PM. Azithromycin for cystic fibrosis. Eur Respir J. 2004;24(5):834–838.
    1. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849–853.
    1. Zureik MBA, Neukirch C, Courbon D, Bean K, Thomas F, Ducimetiere P. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med. 2001;164:2181–2185.
    1. Sin DD, Man SE. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514–1519.
    1. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283.
    1. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560.
    1. Johnston A, Mannino D, Hagan G, Davis K, Kiri V. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle aged cohort. Thorax. 2008 Epub ahead of print.
    1. Tabak CF, Heederik D, Kromhout D, Menotti A. Fruit and fish consumption: A possible explanation for population differences in copd mortality (the seven countries study) Eur J Clin Nutr. 1998;52:819–825.
    1. Grievink LS, Ocke MC, Van’t Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: The morgen study. Thorax. 1998;53:166–171.
    1. Schols AMWJSJ, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. 1998;157:1791–1797.
    1. Gray-Donald KGL, Shapiro SH, Macklem PT, JGM Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:961–966.
    1. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with copd: A meta-analysis. Chest. 2000;117(3):672–678.
    1. Schols AM. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management. Eur Respir J. 2003;22(46 suppl):81S–86S.
    1. Fuld JP, Kilduff LP, Neder JA, et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2005;60(7):531–537.
    1. Steiner MC, Barton RL, Singh SJ, Morgan MDL. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: A randomised controlled trial. Thorax. 2003;58(9):745–751.
    1. Creutzberg EC, Schols AMWJ, Weling-Scheepers CAPM, Buurman WA, Wouters EFM. Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(3):745–752.
    1. Schols AMWJ SP, Dingemans MC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable copd eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993
    1. Mostert R GA, Weling-Scheepers C, Wouters EFM, Schols AMW. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94:859–867.
    1. MacDougall JD, Sutton JR, et al. Operation everest ii: Structural adaptations in skeletal muscle in response to extreme simulated altitude. Acta Physiol Scand. 1991;142:421–427.
    1. Decramer M LL, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med. 1994;150:11–16.
    1. Schols AMWJ BW, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51:819–824.
    1. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: Underlying mechanisms and therapy perspectives. Am J Clin Nutr. 2000;71(5):1033–1047.
    1. Sin DDMS. Is inflammation good, bad or irrelevant for skeletal muscles in copd. Thorax. 2008;63:95–96.
    1. Green RH, Singh SJ, Williams J, Morgan MDL. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2001;56(2):143–145.
    1. Ionescu AA, Schoon E. Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(46 suppl):S64–75.
    1. Slemenda CW, Longcope C, Johnston CC., Jr Cigarette smoking, obesity, and bone mass. J Bone Miner Res. 1989;4(5):737–741.
    1. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(3):704–709.
    1. Vrieze A, Wijkstra PJ, Wempe JB. Low bone mineral density in copd patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007;18(9):1197–202.
    1. Riancho J, Gonzalez Macias J, Del Arco C, Amado J, Freijanes J, Anton M. Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease. Thorax. 1987;42(12):962–966.
    1. Leech J, Dulberg C, Kellie S, et al. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis. 1990;141:68–71.
    1. Gluck O, Colice G. Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases. Chest. 2004;125(5):1859–1876.
    1. Reid D, Hughes RA, Laan RF, et al. Efficacy and safety of daily rise-dronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trialeuropean corticosteroid-induced osteoporosis treatment study. J Bone Miner Res. 2000;15:1006–1013.
    1. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309–2318.
    1. Saag KG, Emkey R, Schnitzer TJ, et al. The Glucocorticoid-Induced Osteoporosis Intervention Study Group. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299.
    1. Lau EM, Chan YH, Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone. 2001;29(6):506–510.
    1. Winett RA. Potential health-related benefits of resistance training. Preventive Med. 2001;33:503–513.
    1. Brenes GA. Anxiety and chronic obstructive pulmonary disease: Prevalence, impact, and treatment. Psychosom Med. 2003;65:963–970.
    1. Aydin IO. Depression, anxiety comorbidity, and disability in tuberculosis and chronic obstructive pulmonary disease patients: Applicability of ghq-12. Gen Hosp Psychiatry. 2001;23:77–83.
    1. Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39:24–29.
    1. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127:1205–1211.
    1. Sabroe I, Parker LC, Calverley PMA, Dower SK, Whyte MKB. Pathological networking: A new approach to understanding COPD. Thorax. 2007;62(8):733–738.
    1. Hoffman EA, Simon BA, McLennan G. State of the art. A structural and functional assessment of the lung via multidetector-row computed tomography: Phenotyping chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(6):519–532.
    1. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: Insights from recent research. Proc Am Thorac Soc. 2007;4(7):512–521.
    1. Celli BR, Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc. 2006;3(6):461–465.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren